Analysts See $-1.44 EPS for Prothena plc (PRTA); Shorts at DENSO CORPORATION LTD ORD (DNZOF) Lowered By 45.21%

February 2, 2018 - By Winifred Garcia

DENSO CORPORATION LTD ORD (OTCMKTS:DNZOF) had a decrease of 45.21% in short interest. DNZOF’s SI was 240,200 shares in February as released by FINRA. Its down 45.21% from 438,400 shares previously. With 400 avg volume, 601 days are for DENSO CORPORATION LTD ORD (OTCMKTS:DNZOF)’s short sellers to cover DNZOF’s short positions. It closed at $62.59 lastly. It is down 0.00% since February 2, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts expect Prothena Corporation plc (NASDAQ:PRTA) to report $-1.44 EPS on February, 13.They anticipate $0.03 EPS change or 2.13% from last quarter’s $-1.41 EPS. After having $-1.37 EPS previously, Prothena Corporation plc’s analysts see 5.11% EPS growth. The stock decreased 3.52% or $1.47 during the last trading session, reaching $40.33. About 381,787 shares traded. Prothena Corporation plc (NASDAQ:PRTA) has risen 41.05% since February 2, 2017 and is uptrending. It has outperformed by 24.35% the S&P500.

DENSO Corporation supplies automotive technology, systems, and components for automakers. The company has market cap of $48.62 billion. It develops and makes products for hybrid and electric vehicles, gasoline and diesel engine management systems and components, powertrain control systems, starters, and power-generation systems comprising alternators; electronic systems, such as semiconductor sensors, micro electronic devices, and engine electronic control units; and thermal systems, including car and bus air conditioning systems, cooling systems, and components comprising radiators and cooling fans. It has a 17.34 P/E ratio. The firm also provides intelligent transport system products, such as car navigation and electronic toll collection systems; telematics products; driving control and safety products, including airbags sensors and ECUs; and body electronics and meters.

Investors sentiment decreased to 1.65 in 2017 Q3. Its down 0.06, from 1.71 in 2017Q2. It fall, as 12 investors sold Prothena Corporation plc shares while 28 reduced holdings. 20 funds opened positions while 46 raised stakes. 31.24 million shares or 2.01% more from 30.62 million shares in 2017Q2 were reported. 24,197 are held by Proshare Advisors Lc. State Of Wisconsin Board holds 0.01% or 27,000 shares. Parametrica Mngmt holds 0.13% of its portfolio in Prothena Corporation plc (NASDAQ:PRTA) for 4,745 shares. Axa holds 0.04% or 144,465 shares in its portfolio. Putnam Investments Limited Company reported 259,387 shares. Guggenheim Capital Ltd Liability Company holds 71,841 shares. Amer Interest Gru has invested 0.01% in Prothena Corporation plc (NASDAQ:PRTA). Jnba Fincl owns 14 shares. Swiss State Bank reported 0% stake. Pacad Investment Ltd owns 1,900 shares for 0.03% of their portfolio. Dupont Cap Corp has invested 0.02% of its portfolio in Prothena Corporation plc (NASDAQ:PRTA). Winslow Evans Crocker owns 0.01% invested in Prothena Corporation plc (NASDAQ:PRTA) for 500 shares. Morgan Stanley reported 89,354 shares stake. 7,042 are held by D E Shaw &. Royal Bancshares Of Canada invested in 26,864 shares or 0% of the stock.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The company has market cap of $1.55 billion. It is developing antibody product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating Parkinson??s disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. It currently has negative earnings. The firm has a license, development, and commercialization agreement with F.

Among 14 analysts covering Prothena Corp (NASDAQ:PRTA), 13 have Buy rating, 0 Sell and 1 Hold. Therefore 93% are positive. Prothena Corp had 29 analyst reports since July 22, 2015 according to SRatingsIntel. SunTrust initiated Prothena Corporation plc (NASDAQ:PRTA) rating on Wednesday, December 21. SunTrust has “Buy” rating and $75 target. The company was maintained on Friday, February 19 by Wedbush. On Thursday, November 19 the stock rating was maintained by RBC Capital Markets with “Outperform”. The rating was maintained by Cantor Fitzgerald on Wednesday, November 8 with “Buy”. The rating was maintained by RBC Capital Markets with “Buy” on Thursday, November 2. The stock of Prothena Corporation plc (NASDAQ:PRTA) has “Buy” rating given on Thursday, July 6 by Oppenheimer. Deutsche Bank maintained the shares of PRTA in report on Monday, October 23 with “Buy” rating. The firm earned “Buy” rating on Monday, December 4 by Oppenheimer. The stock of Prothena Corporation plc (NASDAQ:PRTA) has “Neutral” rating given on Monday, November 20 by Wedbush. Cantor Fitzgerald maintained Prothena Corporation plc (NASDAQ:PRTA) on Thursday, September 28 with “Buy” rating.